<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app12.us.archive.org';v.server_ms=366;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml', '20171003012512')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171003012512/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171003012512/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171003012512" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930221420/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 01:25:12 Oct 03, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930221420/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml" title="22:14:20 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 01:25:12 Oct 03, 2017">03</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930221420/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 01:25:12 Oct 03, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171003012512*/https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 03 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10579?contentType=xml","2017-10-03",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, Saad WA, Standards of Practice Committee, Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012 Jun;23(6):727-36. [89 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22513394&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman DA, Cardella JF, Standards of Practice Committee with Cardiovascular and Interventional [trunc]. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S240-9. [56 references]</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Recommendations for Preprocedure Testing and Management</strong></p>
<p>Assessment and preparation of the patient before image-guided procedures will vary according to the procedure to be performed in conjunction with a comprehensive assessment of the patient's comorbidities. Although image guidance is likely to make minimally invasive procedures more accurate, for example, in their ability to target lesions or to put effector devices such as needles or catheters in optimal position, by their very nature, these procedures preclude the operator from direct visualization of postprocedural bleeding. The lack of available randomized, controlled studies specific to image-guided percutaneous procedures has resulted in considerable variety in clinical practice. In addition, it is doubtful that one can extrapolate the results from open surgical procedures to minimally invasive procedures because of the aforementioned separation of the operator from direct assessment of bleeding (and the associated ability to control it) at the site of the procedure.</p>
<p>Recommendations for patient evaluation and general indications for the use of blood products and other hemostatic agents are outlined in in the tables below. Where reliable data were lacking, recommendations were derived by Delphi consensus of a panel of expert practitioners. The tables represent the results of the Delphi consensus panel, which were derived for the management of a patient with a single hemostatic defect. A total of 18 Certificate of Added Qualification&amp;ndash;certified interventional radiologists participated in a four-round Delphi process. Although representative procedures were placed into one of three categories of risk, as outlined in the tables below, the panel believed there was significant potential variability in risk from procedure to procedure within each category, depending on the individual patient comorbidities and possible multiple concomitant hemostatic defects. It must be stressed, therefore, that specific assessment of bleeding risk and considerations for the use of blood products or other hemostatic agents must be individualized to the patient at the total discretion of the performing physician, who must, at the time of the procedure, make clinical decisions based on an often complex array of patient variables, comorbidities, and concomitant hemostatic defects. With respect to the categories in the tables below, any individual procedure might possibly be treated at a higher risk level, depending on these individual patient factors. In addition, for the purposes of this document, the Delphi consensus panel treated the procedures as elective, with a single hemostatic defect. Emergency indications, multiple concomitant hemostatic defects, and the use of topical or intravascular/perivascular closure devices were not specifically addressed. Numerous maneuvers and modifications, such as needle tract embolization, have been employed to potentially reduce bleeding risks; however, there is no concrete evidence-based research showing their added efficacy, and therefore they will not be further delineated. Emergency or highly urgent procedures, in which the risk of procedural delay may outweigh the potential hemorrhagic risk, may not afford the time for equivalent correction of hemostatic defects as may be achieved in elective procedures. The physician must take into account pathophysiologic, psychosocial, medicolegal, and religious variables in coming to an overall assessment of the patient. For example, periprocedural management for percutaneous liver biopsy may vary significantly between one patient with an international normalized ratio (INR) of 1.7 with no comorbidities and a second patient with INR of 1.7 and concomitant renal failure and cirrhosis.</p>
<p>As there is no evidence to support the use of bleeding times before minimally invasive procedures, the Delphi consensus panel did not address the use of this test. In addition, the use of recombinant factor VIIa was not addressed. Nonsteroidal anti-inflammatory drug (NSAID) use was not specifically addressed by the panel. Although NSAIDs can inhibit platelet function, the effect is reversible with clearance of the drug. Furthermore, NSAIDs tend to cause bleeding mostly in patients with preexisting coagulopathies. Low-molecular-weight heparin (LMWH) was considered by the panel with respect to therapeutic dosing.</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Category 1: Procedures with Low Risk of Bleeding, Easily Detected and Controllable&quot;>
    <thead>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;>Category 1: Procedures with Low Risk of Bleeding, Easily Detected and Controllable</th>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Procedures</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Preprocedure Laboratory Testing</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td>Vascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Dialysis access interventions </li>
                <li>Venography </li>
                <li>Central line removal </li>
                <li>IVC filter placement </li>
                <li>PICC line placement </li>
            </ul>
            Nonvascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Drainage catheter exchange (biliary, nephrostomy, abscess catheter) </li>
                <li>Thoracentesis </li>
                <li>Paracentesis </li>
                <li>Superficial aspiration and biopsy (excludes intrathoracic or intraabdominal sites): thyroid, superficial lymph node </li>
                <li>Superficial abscess drainage </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR: routinely recommended for patients receiving warfarin anticoagulation or with known or suspected liver disease </li>
                <li>aPTT: routinely recommended for patients receiving intravenous unfractionated heparin </li>
                <li>Platelet count: not routinely recommended </li>
                <li>Hematocrit: mot routinely recommended </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR &amp;gt;2.0: threshold for treatment (i.e., FFP, vitamin K) </li>
                <li>PTT: no consensus </li>
                <li>Hematocrit: no recommended threshold for transfusion </li>
                <li>Platelets: transfusion recommended for counts &amp;lt;50,000/&amp;micro;l </li>
                <li>Clopidogrel: withhold for 5 days before procedure </li>
                <li>Aspirin: do not withhold </li>
                <li>LMWH (therapeutic dose): withhold one dose before procedure </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;>There was an 80% consensus on each of these recommendations unless stated otherwise. The management recommendations for each coagulation defect and drug assume that no other coagulation defect is present and that no other drug that might affect coagulation status has been administered. 1-Deamino-8-D-arginine vasopressin may be indicated before image-guided procedures in patients with hemophilia and von Willebrand's disease. </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><span class=&quot;Note&quot;>Abbreviations: aPTT = activated partial thromboplastin time, FFP = fresh frozen plasma, INR = international normalized ratio, IVC = inferior vena cava, LMWH = low-molecular-weight heparin, PICC = peripherally inserted central catheter, PTT = partial thromboplastin time.</span></td>
        </tr>
    </tbody>
</table>
<p>&amp;nbsp;</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Category 2: Procedures with Moderate Risk of Bleeding&quot;>
    <thead>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;>Category 2: Procedures with Moderate Risk of Bleeding</th>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Procedures</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Preprocedure Laboratory Testing</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Vascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Angiography, arterial intervention with access size up to 7 F </li>
                <li>Venous interventions </li>
                <li>Chemoembolization </li>
                <li>Uterine fibroid embolization </li>
                <li>Transjugular liver biopsy </li>
                <li>Tunneled central venous catheter </li>
                <li>Subcutaneous port device </li>
            </ul>
            Nonvascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Intraabdominal, chest wall, or retroperitoneal abscess drainage or biopsy </li>
                <li>Lung biopsy </li>
                <li>Transabdominal liver biopsy (core needle) </li>
                <li>Percutaneous cholecystostomy </li>
                <li>Gastrostomy tube: initial placement </li>
                <li>Radiofrequency ablation: straightforward </li>
                <li>Spine procedures (vertebroplasty, kyphoplasty, lumbar puncture, epidural injection, facet block) </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR: recommended </li>
                <li>aPTT: recommended in patients receiving intravenous unfractionated heparin </li>
                <li>Platelet count: not routinely recommended </li>
                <li>Hematocrit: not routinely recommended </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR: correct to &amp;lt;1.5 </li>
                <li>aPTT: no consensus (trend toward correcting for values &amp;gt;1.5&amp;times; control, 73% consensus) </li>
                <li>Platelets: Transfusion recommended for counts &amp;lt;50,000/&amp;micro;l </li>
                <li>Hematocrit: no recommended threshold for transfusion </li>
                <li>Clopidogrel: withhold for 5 days before procedure </li>
                <li>Aspirin: do not withhold </li>
                <li>LMWH (therapeutic dose): Withhold one dose before procedure </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><span class=&quot;Note&quot;>Abbreviations: aPTT = activated partial thromboplastin time, INR = international normalized ratio, LMWH = low-molecular-weight heparin.</span></td>
        </tr>
    </tbody>
</table>
<p>&amp;nbsp;</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Category 3: Procedures with Significant Bleeding Risk, Difficult to Detect or Control&quot;>
    <thead>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;>Category 3: Procedures with Significant Bleeding Risk, Difficult to Detect or Control</th>
        </tr>
        <tr>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Procedures</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Preprocedure Laboratory Testing</th>
            <th class=&quot;Center&quot; valign=&quot;top&quot;>Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Vascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>TIPS </li>
            </ul>
            Nonvascular:
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>Renal biopsy </li>
                <li>Biliary interventions (new tract) </li>
                <li>Nephrostomy tube placement </li>
                <li>Radiofrequency ablation: complex </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR: routinely recommended </li>
                <li>aPTT: routinely recommended in patients receiving intravenous unfractionated heparin infusion. No consensus on patients not receiving heparin </li>
                <li>Platelet count: routinely recommended </li>
                <li>Hematocrit: routinely recommended </li>
            </ul>
            </td>
            <td valign=&quot;top&quot;>
            <ul style=&quot;list-style-type: disc;&quot;>
                <li>INR: correct to &amp;lt;1.5 </li>
                <li>aPTT: stop or reverse heparin for values &amp;gt;1.5 times control </li>
                <li>Platelets &amp;lt;50,000: transfuse </li>
                <li>Hematocrit: no recommended threshold for transfusion </li>
                <li>Clopidogrel: withhold for 5 days before procedure </li>
                <li>Aspirin: withhold for 5 days </li>
                <li>Fractionated heparin: withhold for 24 hours or up to 2 doses </li>
            </ul>
            </td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;>There was an 80% consensus on each of these recommendations unless stated otherwise. The management recommendations for each coagulation defect and drug assume that no other coagulation defect is present and that no other drug that might affect coagulation status has been administered. 1-Deamino-8-D-arginine vasopressin may be indicated before image-guided procedures in patients with hemophilia and von Willebrand's disease.</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot; colspan=&quot;3&quot;><span class=&quot;Note&quot;>Abbreviations: aPTT = activated partial thromboplastin time, INR = international normalized ratio, TIPS = transjugular intrahepatic portosystemic shunt.</span></td>
        </tr>
    </tbody>
</table>
<p><strong>Summary</strong></p>
<p>In the original guideline document, the guideline committee attempts to summarize some of the available literature regarding periprocedural surveillance and management of hemostatic defects in patients undergoing percutaneous image-guided procedures. Because of the lack of randomized controlled studies or other high-level evidence on this topic, a Delphi panel of experts constructed a set of consensus guidelines to hopefully serve as a reference for the practicing interventionalist in constructing their individual practice guidelines. Although it is likely that individual practice parameters will vary from this document, each practitioner should monitor outcomes and look for trends, both positive and negative, which may suggest modifications or adjustments to these parameters. Outlining bleeding complication rates for specific procedures is beyond the scope of this document and, in many cases, may be difficult or impossible to accurately accomplish because of the lack of high-level data. Where external benchmarks are not available, practitioners may choose to benchmark against their own historical data as part of an overall quality improvement program.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Coagulation abnormalities leading to bleeding complications during percutaneous image-guided interventions</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Evaluation"/>
      <fieldvalue value="Management"/>
      <fieldvalue value="Prevention"/>
      <fieldvalue value="Risk Assessment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Hematology"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Preventive Medicine"/>
      <fieldvalue value="Radiology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>To provide recommendations for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions </li>
    <li>To summarize some of the available literature regarding periprocedural surveillance and management of hemostatic defects in patients undergoing percutaneous image-guided procedures </li>
</ul>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients with abnormal coagulation parameters undergoing percutaneous image-guided interventions</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Assessment</strong></p>
<ol style=&quot;list-style-type: decimal;&quot;>
    <li>Assessment of risk factors and comorbidities </li>
    <li>Assessment of coagulation status using the following tests
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>International normalized ratio (INR)/prothrombin time (PT) </li>
        <li>Activated partial thromboplastin time (aPTT) </li>
        <li>Platelet count </li>
        <li>Hematocrit </li>
    </ul>
    </li>
</ol>
<p><strong>Management/Prevention</strong></p>
<ol style=&quot;list-style-type: decimal;&quot;>
    <li>Management for procedures with low risk of bleeding
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Fresh frozen plasma (FFP) and vitamin K </li>
        <li>Platelet transfusion </li>
        <li>Withholding clopidogrel for 5 days before procedure </li>
        <li>No withholding of aspirin </li>
        <li>Withholding of one therapeutic dose of low-molecular-weight heparin (LMWH) before procedure </li>
    </ul>
    </li>
    <li>Management for procedures with moderate risk of bleeding
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Correcting INR and aPTT before procedure </li>
        <li>Platelet transfusion </li>
        <li>Withholding clopidogrel for 5 days before procedure </li>
        <li>No withholding of aspirin </li>
        <li>Withholding one therapeutic dose of LMWH before procedure </li>
    </ul>
    </li>
    <li>Management for procedures with significant bleeding risk difficult to detect or control
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Correcting INR before procedure </li>
        <li>Stopping or reversing heparin </li>
        <li>Platelet transfusion </li>
        <li>Withholding clopidogrel and aspirin for 5 days before procedure </li>
        <li>Withholding fractionated heparin for 24 h or up to two doses </li>
    </ul>
    </li>
</ol></div>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Risk and incidence of bleeding during percutaneous image-guided interventions</p></div>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An in-depth literature search was performed by using electronic medical literature databases (mainly PubMed searching from 1974 to 2012). Search terms included <em>minimally invasive procedure, coagulation management, anticoagulation management, periprocedural, hemostasis, Coumadin, heparin, aspirin, clopidogrel, biopsy, endovascular, bleeding risk, blood transfusion, fresh frozen plasma</em>.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A critical review of peer-reviewed articles is performed with regard to the study methodology, results, and conclusions. The qualitative weight of these articles is assembled into an evidence table, which is used to write the document such that it contains evidence-based data with respect to content, complication rates, outcomes, and thresholds for prompting quality assurance reviews.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Delphi)"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Standards documents of relevance and timeliness are conceptualized by the Standards of Practice Committee members. A recognized expert is identified to serve as the principal author for the standard. Additional authors may be assigned depending on the magnitude of the project.</p>
<p>When the evidence of literature is weak, conflicting, or contradictory, consensus for the parameter is reached by a minimum of 12 Standards of Practice Committee members by using a modified Delphi consensus method. For the purposes of these documents, consensus is defined as 80% Delphi participant agreement on a value or parameter.</p>
<p>Eighteen Certificate of Added Qualifications&amp;ndash;certified members of the Society of Interventional Radiology (SIR) Standards of Practice Committee participated through four rounds of the Delphi to reach consensus as reported.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The draft document is critically reviewed by Standards of Practice Committee members, either by telephone conference calling or face-to-face meeting. The finalized draft from the Committee is sent to the Society of Interventional Radiology (SIR) membership for further input/criticism during a 30-day comment period. These comments are discussed by the Standards of Practice Committee and appropriate revisions made to create the finished standards document. Before its publication, the document is endorsed by the SIR Executive Council.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Appropriate periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Protamine's half-life is short and ranges from 5 to 7.5 minutes, which can lead to &quot;paradoxical&quot; re-anticoagulation after protamine administration. Side effects of protamine include hypotension, bradycardia, pulmonary arterial hypertension, decreased oxygen consumption, and anaphylactoid reactions. </li>
    <li>Intravenous administration of vitamin K is associated with a risk of anaphylactoid reaction. The U.S. Food and Drug Administration has issued a &quot;black box&quot; warning for the subcutaneous, intravenous, and intramuscular routes of administration due to reports of severe reactions, including fatalities. </li>
    <li>The use of fresh frozen plasma (FFP) in nonbleeding cases before image-guided interventions must be weighed against the potential risks of transfusion. An increasingly recognized and often life-threatening complication, transfusion-related acute lung injury, has an insidious onset characterized by hypoxia, dyspnea, and volume overload, occurring after transfusion of approximately 1 in 8,000&amp;ndash;60,000 U of FFP. The ability of patients with congestive heart failure or other similar conditions to handle the volume and rate at which transfusions may occur are limited and should be addressed accordingly. Other important transfusion-related complications include allergic or anaphylactic reactions, transmittal of infectious diseases including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C, albeit rarely, and acute hemolysis secondary to anti-A or anti-B antibodies. </li>
    <li>Similar to the plasma-rich product FFP, platelets are also associated with a multitude of risks, including transfusion-related acute lung injury, anaphylaxis, and viral/bacterial contamination. One study reported that, with increasing number of platelet transfusions, the effectiveness progressively decreased, even when lymphocytotoxic antibody-positive patients were removed from the analysis. The judicious use of platelet transfusion may reduce the overall benefit in a time of need, such as in the setting of active bleeding. </li>
    <li>Refer to the &quot;Efficacy and Complications&quot; section of the original guideline document for a discussion of bleeding complications, including life-threatening or fatal bleeding, with antiplatelet therapy in image-guided procedures. </li>
</ul>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Although it is likely that individual practice parameters will vary from this document, each practitioner should monitor outcomes and look for trends, both positive and negative, which may suggest modifications or adjustments to these parameters. Outlining bleeding complication rates for specific procedures is beyond the scope of this document and, in many cases, may be difficult or impossible to accurately accomplish because of the lack of high-level data. Where external benchmarks are not available, practitioners may choose to benchmark against their own historical data as part of an overall quality improvement program. </li>
    <li>The clinical practice guidelines of the Society of Interventional Radiology (SIR) attempt to define practice principles that generally should assist in producing high quality medical care. These guidelines are voluntary and are not rules. A physician may deviate from these guidelines, as necessitated by the individual patient and available resources. These practice guidelines should not be deemed inclusive of all proper methods of care or exclusive of other methods of care that are reasonably directed towards the same result. Other sources of information may be used in conjunction with these principles to produce a process leading to high quality medical care. The ultimate judgment regarding the conduct of any specific procedure or course of management must be made by the physician, who should consider all circumstances relevant to the individual clinical situation. Adherence to the SIR Quality Improvement Program will not assure a successful outcome in every situation. It is prudent to document the rationale for any deviation from the suggested practice guidelines in the department policies and procedure manual or in the patient's medical record. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Safety"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, Saad WA, Standards of Practice Committee, Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012 Jun;23(6):727-36. [89 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22513394&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2009 Jul (revised 2012 Jun)"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Society of Interventional Radiology - Medical Specialty Society"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Society of Interventional Radiology</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Society of Interventional Radiology Standards of Practice Committee</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Committee Members</em>: Indravadan J. Patel, MD, Department of Radiology, University Hospitals Case Medical Center, Cleveland, Ohio; Jon C. Davidson, MD, Department of Radiology, University Hospitals Case Medical Center, Cleveland, Ohio; Boris Nikolic, MD, MBA, Department of Radiology, Albert Einstein Medical Center, Philadelphia, Pennsylvania; Gloria M. Salazar, MD, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Marc S. Schwartzberg, MD, Radiology Associates of Central Florida, Leesburg, Florida; T. Gregory Walker, MD, Section of Cardiovascular Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts; Wael A. Saad, MD, Department of Radiology, University of Virginia Health System, Charlottesville, Virginia</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None of the authors have identified a conflict of interest.</p></div>"/>
    </field>
    <field fieldid="159" ordby="1255" id="453" name="Guideline Endorser(s)" type="orglist">
      <fieldvalue value="Cardiovascular and Interventional Radiological Society of Europe - Nonprofit Organization"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman DA, Cardella JF, Standards of Practice Committee with Cardiovascular and Interventional [trunc]. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S240-9. [56 references]</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.sirweb.org/clinical/cpg/4E8CAd01.pdf&quot; title=&quot;Society of Interventional Radiology Web site&quot;>Society of Interventional Radiology Web site</a>.</p>
<p>Print copies: Available from the Society of Interventional Radiology, 10201 Lee Highway, Suite 500, Fairfax, VA 22030.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on August 19, 2011. The information was verified by the guideline developer on September 8, 2011. This summary was updated by ECRI Institute on March 10, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins. This summary was updated by ECRI Institute on January 23, 2015.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 01:25:12 Oct 03, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 23:43:44 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 183.449 (3)
  esindex: 0.007
  captures_list: 199.963
  CDXLines.iter: 13.066 (3)
  PetaboxLoader3.datanode: 161.568 (4)
  exclusion.robots: 0.364
  exclusion.robots.policy: 0.349
  RedisCDXSource: 0.646
  PetaboxLoader3.resolve: 125.746
  load_resource: 155.842
-->